Immunotherapy of non-Hodgkin's lymphoma with hLL2 (epratuzumab, an anti-CD22 monoclonal antibody) and Hu1D10 (apolizumab)

This publication has 35 references indexed in Scilit:

• Growth Inhibition of CD20‐positive B Lymphoma Cell Lines by IDEC‐C2B8 Anti‐CD20 Monoclonal Antibody
  Japanese Journal of Cancer Research, 1998
• Construction and characterization of a humanized, internalizing, B-cell (CD22)-specific, leukemia/lymphoma antibody, LL2
  Molecular Immunology, 1995
• The Amino-terminal Immunoglobulin-like Domain of Sialoadhesin Contains the Sialic Acid Binding Site
  Published by Elsevier ,1995
• Ligation of HLA class II molecules promotes sensitivity to CD95 (Fas antigen, APO‐1)‐mediated apoptosis
  European Journal of Immunology, 1995
• Effect of VK framework‐1 glycosylation on the binding affinity of lymphoma‐specific murine and chimeric LL2 antibodies and its potential use as a novel conjugation site
  International Journal of Cancer, 1995
• Sialoadhesin, myelin-associated glycoprotein and CD22 define a new family of sialic acid-dependent adhesion molecules of the immunoglobulin superfamily
  Current Biology, 1994
• Lymphocyte programmed cell death is mediated via HLA class II DR
  International Immunology, 1994
• Association of CD22 with the B cell antigen receptor
  European Journal of Immunology, 1993
• A phase 1a clinical trial of LYM‐1 monoclonal antibody serotherapy in patients with refractory b cell malignancies
  Hematological Oncology, 1989
• Treatment of B-Cell Lymphoma with Monoclonal Anti-Idiotype Antibody
  New England Journal of Medicine, 1982